70 results about "Human colon" patented technology

The present invention relates to novel colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon or colon cancer antigens," and the use of such colon or colon cancer antigens for detecting disorders of the colon, particularly the presence of colon cancer and colon cancer metastases. More specifically, isolated colon or colon cancer associated nucleic acid molecules are provided encoding novel colon or colon cancer associated polypeptides. Novel colon or colon cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human colon or colon cancer associated polynucleotides and / or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and / or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and / or compositions for inhibiting the production and function of the polypeptides of the present invention.

Methods of modifying therapeutic compounds such as drugs to be substrates for active transporters expressed in epithelial cells lining the lumen of the human colon are disclosed. The transporters expressed in the human colon include the sodium dependent multi-vitamin transporter (SMVT), and monocarboxylate transporters 1 and 4 (MCT 1 and MCT 4). The modified compounds can themselves be pharmacologically active, or upon cleavage of a chemical moiety after uptake from the colon, can be metabolized to form a compound that is pharmacologically active (e.g., a prodrug). The modified compounds disclosed herein are suitable for use in extended release oral dosage forms, particularly those that release drug over periods of greater than about 2-4 hours following administration.

The present application provides novel human genes RNF43 whose expression is markedly elevated in colorectal cancers, as well as CXADRL1 and GCUD1 whose expression is markedly elevated in gastric cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease.

Methods and compositions are disclosed for inhibiting proliferation of human colon adenocarcinoma cells, reducing pro-inflammatory molecules, adhesion molecules, and vascular smooth muscle cell proliferation, and for increasing NO production. The present invention describes the use of phenolic compositions, purified from oats or synthetically produced, to decrease the effective amount of pro-inflammatory molecules and / or cell adhesion molecules. Alternatively, an alcoholic extract or concentrate from oats can be used. The methods of the present invention can be used as a treatment or prophylaxis of a wide variety of disorders associated with inflammatory states and / or with a lack of or need for nitric oxide (NO), such as inflammatory conditions, pain, free radical associated disorders, cardiovascular diseases, autoimmune disorders, pathological platelet aggregation, pathological vasoconstriction, vascular effects of diabetes, stroke, atherosclerosis, hypertension, abnormal vasospasm, and restenosis after angioplasty.

Monoclonal antibodies, in particular 33.28 and 31.1, and chimeric antibodies, in particular mouse / humans chimeric Chi #1 specific for glycoprotein antigens of colon carcinoma-associated antigens which are immunogenic in humans, are disclosed. Such antibodies, and fragments and derivatives thereof, are useful in immunodiagnosis and immunotherapy of human colon, breast, and ovarian cancer, and for purification of antigens which can serve as immunotherapeutic agents. Methods of detecting the colon carcinoma-associated antigen in a sample, and methods for treating subjects having colon, breast, and ovarian carcinomas are disclosed.

The invention discloses a compound with antitumor activity and a preparation method and application of the compound and belongs to the technical fields of new compound synthesis and medicine application. According to the compound, the preparation and the application thereof disclosed by the invention, aromatic aldehyde and aromatic ketone are catalyzed by sodium hydroxide to synthesize 3,4,5-triethoxy-3',4'-dimethoxy chalcone for the first time, and the test of in vitro tumor cell inhibitory activity on the 3,4,5-triethoxy-3',4'-dimethoxy chalcone is realized; the result shows that the compound has higher inhibitory activity for human lung cancer cell A549, human colon carcinoma cell SW620 and human liver cancer cell HepG2. In addition, the antitumor activity of the 3,4,5-triethoxy-3',4'-dimethoxy chalcone for the human colon carcinoma cell SW620 and the human liver cancer cell HepG2 is superior to that of a reference drug 5-fluorouracil. The invention provides a new effective treatment means for tumor treatment and has a broad application prospect.

The invention relates to a method and kit for detecting gene mutations, particularly a method and kit for detecting KRAS gene 12, 13 codon mutations. The kit comprises a PCR (Polymerase Chain Reaction) buffer solution, a dNTP (deoxyribonucleotide triphosphate), a DNA (deoxyribonucleic acid) polymerase, a specific primer pair, fluorescent dye, water, a specific probe and a wild-type control. The kit is characterized in that the DNA polymerase is a HotStarTaq DNA polymerase, and the fluorescent dye is SYTO9 fluorescent dye. The method comprises the following steps: (1) acquiring a genome DNA to be analyzed according to a conventional method; (2) carrying out PCR amplification on the genome DNA to obtain a PCR amplified product; after the reaction finishes, carrying out denaturation and renaturation on the PCR product; and (3) carrying out melting curve analysis on the PCR amplified product, and comparing with a melting curve generated by the PCR amplified product of the wild-type genome DNA, wherein the melting curve generated by the PCR amplified product of the mutant genome DNA firstly descends.

An organotypic culture comprises an artificial stroma overlayed with epithelial cells isolated from a human colon or intestine. The stroma comprises a mixture of collagen and human fibroblasts isolated from a human colon or intestine. The culture contains a factor that binds the IGF-1 receptor, a factor that binds the EGF receptor, and a factor that binds the LIF receptor. These factors may be added exogenously to the culture via medium or may be expressed by various recombinantly engineered cell types in the culture. The organotypic culture can result in growth that is in situ-like or emphasizes other physiological or morphological states, depending on the balance of factors in the growth media. The organotypic culture may be used in methods for screening of therapeutic, carcinogenic, or growth enhancement factors, or for treating intestinal injuries by applying to the site of an injury the intact culture or the components thereof.

The invention discloses use of dihydroartemisinin in preparation of a drug for inhibition of tumour growth, and the tumour is liver cancer tumor, breast cancer tumor, melanoma or intestinal cancer tumor. The liver cancer tumor is human liver cancer HepG-2, human liver cancer QGY and human liver cancer SMMC. The breast cancer tumor is human breast cancer Bcap-37.The intestinal cancer tumor is human colon carcinoma Colo-205. The drug for inhibition of tumour growth may also include one of artemisinin and artemisinin derivative. The dihydroartemisinin can be used in preparation of the drug for inhibition of tumour growth, and is obvious in anti-cancer effect, small in side effect of chemotherapy, safe to use, and low in drug cost.

Human Colon Specific Polynucleotides (DNA and RNA), Polypeptides, and Antibodies, as well as methods for using and producing such polynucleotides, polypeptides, and antibodies are disclosed. More particularly, methods are disclosed for utilizing such polynucleotides, polypeptides, and antibodies to detect, diagnose, prevent, treat, and / or ameliorate cancer (particularly gastrointestinal tract cancers such as colon and pancreatic cancer). Also disclosed are compositions and methods for targeting and destroying cancer cells (particularly gastrointestinal tract cancers such as colon and pancreatic cancer) via the Colon Specific Protein and / or via the Colon Specific Protein Receptor. Moreover, methods of screening for antagonists and binding partners of the Colon Specific Protein and therapeutic uses of such antagonists and binding partners are also disclosed.

The invention relates to an inulin biscuit, which consists of the following raw materials in part by weight: 100 parts of flour, 5 to 100 parts of inulin, 4 to 12 parts of sweetener, 0.5 to 2.5 parts of phospholipid, 1.0 to 8 parts of condiment, 0.2 to 2 parts of sodium bicarbonate, 8 to 20 parts of vegetable oil, 8 to 20 parts of milk powder and 2 to 12 parts of fresh eggs. The inulin biscuit which is prepared by mixing the raw materials has the advantages of high nutritive value, attractive appearance and color, low caloric value, good brittleness and mouthfeel, and has the effects that (1) the caloric value is low; (2) the growth of probiotics of human colons is promoted, toxic fermentation products are inhibited, and the defecation frequency and defecation weight are increased; (3) the acidity of excrement is increased, and colon cancer is prevented; (4) the absorption of mineral substance such as calcium, magnesium and iron is promoted; and (5) the physiological functions of body immunity and the like are enhanced. The inulin biscuit can improve the nutritive value while keeping the excellent tissue state and mouthfeel of the biscuit.

The present invention provides a robotic locomotive device (1) that is capable of driving itself forwards and backwards, anchoring and steering itself whilst inside a tubular structure (200), for example, the human colon, or any structure comprising two opposing walls (202, 204). In this respect, the device is made up of two or three segments (102, 104, 106) covered in an elastic material and driven by an internal actuating mechanism. All of the segments (102, 104, 106) have a concertina configuration that enable a shortening and lengthening motion. As well as contracting and extending in length, at least one of the end segments (102, 106) is capable of bending at an angle away from the longitudinal axis such that it becomes wedged or jammed between the walls (202, 204) of the tubular structure (200). That is, the end segments (102, 106) are capable of both a bending action and a contracting and extending action. The device (1) moves by alternately jamming a segment (102, 104, 106) between the walls (202, 204) of the tubular structure (200), and then contracting or extending the segments (102, 104, 106) to inch the device (1) forward with a more effective locomotive action. As such, the present invention provides a simplified design that is more robust to harsh or unclean environments, whilst still maintaining the level of performance required from such a device.

Oral intake of D-tagatose in a prebiotic food induces production of butyrate and stimulates the growth of beneficial bacteria in the human colon. Therefore it is believed to be useful in food or the like as preventive drug against colon cancer.

The invention provides a human colon carcinoma cell line DXH-1, which is derived from primary lesion of human sigmoid colon carcinoma, and application of the human colon carcinoma cell line as a human colon carcinoma occurrence, human colon carcinoma development or human colon carcinoma transfer cell model, application of the human colon carcinoma cell line in establishing a human colon carcinoma animal model and application of the human colon carcinoma cell line in researching a human colon carcinoma occurrence mechanism and / or medicines for treating the human colon carcinoma. The human colon carcinoma cell line DXH-1 disclosed by the invention can be stably transferred for more than 50 generations, so that an appropriate material is provided for colorectal carcinoma mechanism and drug screening. In an in-vivo nude mice experiment, the human colon carcinoma cell line shows a relatively strong tumorigenesis cavity, and the cell line, transplanted subcutaneously in nude mice by 1*106 cells, is capable of promoting 100% (5 / 5) tumorigenesis after 35 days; the DXH-1 cell has certain drug resistance to colon carcinoma chemotherapeutics (5FU, such as oxaliplatin, irinotecan and the like), so that a material is provided to the researches on a colon carcinoma chemotherapeutic resistance mechanism; and the human colon carcinoma cell line DXH-1 is preserved in China Center for Type Culture Collection in Wuhan University, Wuhan, China with number of CCTCC No: C201543.

Disclosed herein are methods for the in vitro differentiation of a precursor cell into definitive endoderm, which may further be differentiated into a human colonic organoid (HCO), via modulation of signaling pathways. Further disclosed are HCOs and methods of using HCOs, which may be used, for example, for the HCOs may be used to determine the efficacy and / or toxicity of a potential therapeutic agent for a disease selected from colitis, colon cancer, polyposis syndromes, and / or irritable bowel syndrome.

The invention discloses a black phosphorus material as well as a preparation method and application thereof, and belongs to the technical field of two-dimensional materials. The black phosphorus material comprises a black phosphorus unit and an azide high-molecular polymer, wherein the azide high-molecular polymer is connected with the black phosphorus unit through a covalent bond. In the black phosphorus material, the azide high-molecular polymer and the black phosphorus unit form a covalent bond, so that the stability and dispersity of the black phosphorus material in different systems such as water, PBS, a cell culture medium, simulated gastric juice, simulated intestinal juice and human colon fluid are improved, and the black phosphorus material can be widely applied to photothermal therapy of tumors or preparation of black phosphorus nano preparations for oral administration.

The invention relates to an anthraquinone compound derived from aspergillus versicolor and application thereof in preparation of human colon cancer resisting drugs. The compound plays a role in inhibiting proliferation of colon cancer cells. The compound has a structural formula shown in the description. The compound is obtained through carrying out fermentation culturing on aspergillus versicolorIBPT-7 so as to obtain a fermented product and then separating the compound from the fermented product and purifying the compound. Confirmed by experiments, the compound has relatively good anti-tumor activity to human colon cancer cells, i.e., HCT-116. The compound can be applied to research on human colon cancers as a human lung cancer cell proliferation inhibiting drug or anti-tumor drug.

The invention discloses an application of hericium erinaceus polysaccharide in preparation of a product for preventing and treating colon cancer. Experiments prove that the hericium erinaceus polysaccharide can effectively inhibit the growth of human colon cancer cells HCT-116, DLD1 and HT-29; the clone colony forming capacity of HCT-116 cells can be significantly inhibited; the human colon cancerHCT-116 cells can be promoted to apoptosis; and the HCT-116 can be induced to block in an S period, so that colon cancer can be prevented and treated, and therefore the hericium erinaceus polysaccharide has the potential of becoming the functional food or drug for preventing and / or treating colon cancer.

A system and method for reducing the likelihood of colorectal cancer in a human being includes the modification of an individual's gut microbes by employing a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR / Cpf1) system to modify only bacterial genes of bacteria that reside in the human gut that are non-homologous to those encompassed in the human genome, and in particular, to administer a therapeutically effective amount of a bacterial formulation comprising F. prausnitzii that has been modified to produce one of alliin or butyrate.

The invention relates to a method for establishing a model of fluorescence orthotopic transplantation of subcutaneous metastasis organ cancers, which is characterized in that human colon adenocarcinoma cell strains or cancer cell strain green fluorescent proteins (GFP) of corresponding organs are selected; GFP plasmids carry out transfection on cancer cell strains of the organs via retrovirus pLPCX so that the cancer cell strains of the organs contain GFP expression plasmids; a GFP gene is connected with a pLPCX vector via a T4 ligase; a GFP-pLPCX vector is transfected to a PT67 package cell to obtain a Lovo cell; nude mice are selected and subjected to subcutaneous inoculation with Lovo cell suspension; tumors can be formed in about 4 weeks; orthotopic transplantation is carried out after green fluorescence is observed; a cut is opened on the skin and peritoneum; about 1cm cecum of the nude mice is taken out of the peritoneum; the gap between the cecum and the peritoneum is sutured and the cecum is transferred subcutaneously; the cut cecum is subjected to serosa; two fluorescence-carrying tumors with diameter of about 1mm are transplanted to the cecum via the suture and the skin is closed.

A genome wide microarray gene expression approach for human colorectal cancer cells was used to identify hundreds of hypermethylated genes for colon cancer. We compared isogenic cells altered pharmacologically versus genetically to induce genomic demethylation, to pinpoint genes activated by DNA demethylation, but not by inhibition of class I and II histone deacetylases (HDACs). We achieve an 82% success rate in predicting genes with densely hypermethylated CpG islands and complete gene silencing. The genes are similarly hypermethylated in primary tumors and have previously undetected tumor suppressor functions. The genes can be used diagnostically to detect cancer, pre-cancer, and likelihood of developing cancer.

The invention provides a method for evaluating the biosecurity of 76 nm nano silver on the base of intestinal epithelial cells. According to the method, cell lines of human colon carcinoma epithelial cells Caco-2 are selected as an object of study, nano zinc oxide (90.81 nm) with higher cytotoxicity is taken as a positive control, normal cells without the nano material are taken as a blank control, and the cytotoxicity of the nano material is preliminarily explored by an AO / EB double staining method and a CCK-8 method. The oxidative damage effect and the possible mechanism of nano silver on cells are studied by an oxidative stress method through detecting the influence of emission of ROS, SOD and GSH in the cells Caco-2. The result shows that 76.29nm silver particles (smaller than 200 mu g / ml) don't influence the activity of the cells Caco-2 obviously and cause no oxidative stress damage on the cells Caco-2, but the oxidation resistance of the cells is enhanced and is up to the highest level when the concentration of nano silver is 50 mu g / ml.

The invention provides a preparation method of Jieguqili tablet. The Jieguqili tablet is prepared by the following raw medicines by weight: 100g of stir-baked olibanum, 100g of stir-baked myrrh, 150g of angelica sinensis, 250g of ground beetle, 150g of hot rhizoma drynariae, 100g of borax, 150g of sanguis draconis, 100g of calcinated native copper, and 100g of wine-fired rhubarb through adopting a microwave extraction method, so that the content is greatly increased, and the usage amount is reduced. The invention further provides applications of the Jieguqili tablet in preparing drugs for inhibiting proliferation of human colon carcinoma HT29 cells.

Genes and variant RNAs that are differentially expressed in human colon tumor tissues compared with normal colon tissue and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of colon cancer.

The invention belongs to the field of microbial fuel cells and particularly discloses an electrode assembly which can be implanted into a human colon to form a microbial fuel cell. The device comprises a cathode 1, an anode 2 and an attachment bracket 3, wherein the attachment bracket 3 is arranged between the cathode 1 and the anode 2. In the microbial fuel cell formed by the electrode assembly, organic matter is oxidized under the action of anode electricigens to produce electrons reaching the cathode through an external circuit, and simultaneously, protons are spread to the cathode; and as electron acceptors, trace oxygen, carbon dioxide, nitrate and fumaric acid are combined with the electrons and the protons on the cathode to generate reduction reaction to realize an electrogenesis process. The electrode assembly which can be implanted into the human colon to form the microbial fuel cell has a simple structure, can supply power to implantable medical devices by implanting the electrode assembly into a human body to form the microbial fuel cell and has longer service life.